In June 2023, the New England Journal of Medicine published the retatrutide Phase 2 trial results — 24.2% mean weight reduction at the highest dose over 48 weeks. This represented the highest body weight reduction ever published for a pharmacological intervention in a randomised trial. This analysis covers the mechanism, trial design, results, and research implications.
What Is Retatrutide? Triple Agonist Mechanism
Retatrutide (LY3437943) is a single-molecule triple agonist targeting three incretin receptors simultaneously:
Enhanced insulin secretion, possible direct adipose effects
GCGR
Liver, adipose tissue
Hepatic glucose production, adipose lipolysis, increased energy expenditure
The addition of GCGR (glucagon receptor) agonism to GLP-1R + GIPR is the key differentiating feature. Glucagon drives hepatic glucose production and adipose lipolysis — creating a direct fat mobilisation mechanism that dual GLP-1R/GIPR agonists (tirzepatide) lack.
Phase 2 Trial Results (NEJM 2023)
Dose Group
Weight Reduction at Week 48
Responders >15%
Responders >20%
Placebo
-2.1%
N/A
N/A
1 mg weekly
-8.7%
30%
17%
4 mg weekly
-17.5%
66%
42%
8 mg weekly
-24.2%
83%
65%
12 mg weekly
-22.8%
79%
60%
The 24.2% figure in context
For reference: semaglutide 2.4 mg (STEP-1) produced 14.9% weight reduction. Tirzepatide 15 mg (SURMOUNT-1) produced 22.5%. Retatrutide 8 mg produced 24.2% — the highest pharmacologically-achieved weight reduction in a published RCT as of 2023. The 12 mg dose was slightly lower — suggesting a non-linear dose-response at the highest doses.
⚗️
What Makes GCGR Agonism Different?
The glucagon receptor (GCGR) mechanism explains the additional weight loss beyond what dual agonists achieve:
Pathway
Mechanism
Net Effect
GCGR — Hepatic
↑ cAMP → gluconeogenesis/glycogenolysis
↑ hepatic glucose output (countered by GLP-1R insulin effect)
GCGR — Adipose
↑ cAMP → PKA → HSL activation → lipolysis
↑ free fatty acid release → β-oxidation → energy expenditure
GCGR — Thermogenesis
Sympathetic nervous system via CNS GCGR
↑ BAT thermogenesis, ↑ total energy expenditure
In the presence of GLP-1R agonism, the hepatic glucose output from GCGR activation is blunted. What remains is the adipose lipolysis and thermogenic component — pure fat mobilisation without the hyperglycaemia that glucagon alone would produce.
Research Implications for Retatrutide Studies
For preclinical research, retatrutide presents several design opportunities:
Research Question
Design Approach
GCGR contribution to triple agonist efficacy
Retatrutide vs tirzepatide (GLP-1R+GIPR only) head-to-head in DIO mouse
Retatrutide icv vs SC — separates central GLP-1R from peripheral GLP-1R/GIPR/GCGR contributions
Fat mass specificity
EchoMRI time course: fat mass vs lean mass trajectory during retatrutide treatment
Comparison with surgical intervention
Retatrutide vs vertical sleeve gastrectomy — equivalent weight loss, different mechanisms
❓
Frequently Asked Questions
What is retatrutide?
Retatrutide (LY3437943) is a synthetic peptide that simultaneously activates GLP-1R (appetite/gastric emptying), GIPR (insulin potentiation), and GCGR (lipolysis/thermogenesis). It produced 24.2% weight reduction in the NEJM 2023 Phase 2 trial — the highest pharmacologically-achieved figure in a published RCT.
Why does retatrutide produce more weight loss than tirzepatide?
Tirzepatide activates GLP-1R + GIPR. Retatrutide adds GCGR — driving adipose lipolysis and increasing energy expenditure through thermogenic pathways. The GCGR-mediated fat mobilisation adds a weight reduction mechanism that tirzepatide lacks.
What was the Phase 2 trial design?
The NEJM 2023 Phase 2 trial was a double-blind RCT in adults with obesity (BMI ≥27) randomised to placebo or retatrutide at 1/4/8/12 mg SC weekly for 48 weeks. Primary endpoint: percent change in body weight at week 24. The 24.2% figure is from the 8 mg dose arm at week 48 (not primary endpoint timepoint).
Is retatrutide in Phase 3?
Phase 3 trials (TRIUMPH program) were ongoing as of 2025. QSC supplies retatrutide for laboratory research use only — not for human use.
